Cationic betaine precursors to zwitterionic betaines having controlled biological properties
Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems.
1. A surface of a substrate, comprising a polymer covalently coupled thereto, wherein the polymer has the formula:
PB-(L 1 -N + (R a )(R b )-L 2 -A(=O)—OR c ) n (X − ) n
wherein
PB is a polymer backbone;
N + is a cationic center;
R a and R b are independently selected from hydrogen, alkyl, and aryl;
A(=O)—OR c is a hydrolyzable group, wherein A is selected from the group consisting of C, S, SO, P, or PO, and R c is an alkyl, aryl, acyl, or silyl group that may be further substituted with one or more substituents;
L 1 is a linker that covalently couples the cationic center to the polymer backbone;
L 2 is a linker that covalently couples the cationic center to the hydrolyzable group; X—is a counter ion associated with the cationic center; and n is an integer from about 10 to about 10,000.
2. The surface of claim 1 , wherein the counter ion is selected from the group consisting of C1-C20 carboxylates and C1-C20 alkylsulfonates.
3. The surface of claim 1 , wherein the counter ion is a therapeutic agent.
4. The surface of claim 1 , wherein the counter ion is selected from the group consisting of an antimicrobial, an antibacterial, and an antifungal agent.
5. The surface of claim 1 , wherein the counter ion is selected from the group consisting of nucleic acids, amino acids, proteins, and peptides.
6. The surface of claim 1 , wherein the hydrolyzable group releases a C1-C20 carboxylate on hydrolysis.
7. The surface of claim 1 , wherein R a and R b are independently selected from the group consisting of hydrogen and C1-C10 straight chain and branched alkyl groups.
8. The surface of claim 1 , wherein L 1 is selected from the group consisting of —C(═O)O—(CH 2 ) n —and —C(═O)NH—(CH 2 ) n —, wherein n is an integer from 1 to 20.
9. The surface of claim 1 , wherein the L 2 is —(CH 2 ) n —, where n is an integer from 1 to 20.
10. The surface of claim 1 , wherein A is selected from the group consisting of C, SO, and PO.
11. The surface of claim 1 , wherein R c is C1-C20 alkyl.
12. The surface of claim 1 , wherein X- is selected from the group consisting of halide, carboxylate, alkylsulfonate, sulfate, nitrate, perchlorate, tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate, bis(trifluoromethylsulfonyl)amide, lactate, and salicylate.
13. The surface of claim 1 , wherein the polymer has a plurality of repeating units, the repeating units having the formula:
—[CH 2 —C(R d )] n -L 1 -N + (R a )(R b )-L 2 -A(=O)—OR c X −
wherein
—[CH 2 —C(R d )] n - defines a polymer backbone having n repeating units;
R d is selected from the group consisting of hydrogen, fluorine, trifluoromethyl, and C1-C6 alkyl;
n is 10 to 10,000;
N + is a cationic center;
R a and R b are independently selected from hydrogen, alkyl, and aryl;
A(=O)—OR c is a hydrolyzable group, wherein A is selected from the group consisting of C, S, SO, P, or PO, and R c is an alkyl, aryl, acyl, or silyl group that may be further substituted with one or more substituents;
L 1 is a linker that covalently couples the cationic center to the polymer backbone;
L 2 is a linker that covalently couples the cationic center to the hydrolyzable group; and
X − is the counter ion associated with the cationic center.
14. The surface of claim 1 , wherein the polymer is a homopolymer.
15. The surface of claim 1 , wherein the polymer is a copolymer.
16. The surface of claim 1 , wherein the polymer is a random copolymer.
17. The surface of claim 1 , wherein the polymer is a block copolymer.
18. The surface of claim 1 , wherein the substrate is selected from the group consisting of a particle, a drug carrier, a non-viral gene delivery system, a biosensor, a membrane, an implantable sensor, a subcutaneous sensor, an implant, and a contact lens.
19. The surface of claim 1 , wherein the substrate is a medical device.
20. The surface of claim 1 , wherein the substrate is an implantable medical device selected from the group consisting of an ear drainage tube, feeding tube, glaucoma drainage tube, hydrocephalous shunt, keratoprosthesis, nerve guidance tube, urinary catheter, tissue adhesive, x-ray guide, artificial joint, artificial heart valve, artificial blood vessel, pacemaker, left ventricular assist device (LVAD), artery graft, tissue scaffold, and stent.